FIRST EXTENSION - GRANTED
granted
on 05 Jun 2024
Last Applicant/ Owned by
84 Wood Lane
London
GB
W120BZ
Serial Number
97388990 filed on 29th Apr 2022
Registration Number
N/A
Correspondent Address
SUITE 125
BUFFALO GROVE, IL 60089
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
PHENOTYPE LOCK
Chemical and biological preparations for use in science and industry; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Chemical and biological preparations for use in science and industry; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [040]
Treatment & Processing of Materials Services
Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97388990
Mark Type
No Service Mark
Attorney Docket Number
No FBD 0153 US
44D Filed
No
44D Current
No
44E filed
Yes
44E Current
Yes
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 13th Jun 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 05th Jun 2024 | SOU EXTENSION 1 FILED |
| 05th Jun 2024 | SOU EXTENSION 1 GRANTED |
| 05th Jun 2024 | SOU TEAS EXTENSION RECEIVED |
| 14th May 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 19th Mar 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 19th Mar 2024 | PUBLISHED FOR OPPOSITION |
| 28th Feb 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 28th Feb 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 15th Feb 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |